INTRODUCTION 62
Every year, over 1,500,000 individuals in the US are diagnosed with cancer. Cachexia (involuntary 63 loss of muscle and adipose tissue) is present in up to 80% of cancer patients, is strongly associated 64 with higher morbidity and mortality, and is reported as the direct cause of death in 20-40% of these 65 patients (Dewys, Begg et al., 1980 , Fearon, Strasser et al., 2011 . Adipose tissue, once considered 66 only a high-energy fuel reserve, has emerged recently as an active metabolic organ modulating 67 inflammation, energy expenditure and food intake in non-cancer settings (You & Nicklas, 2006) . is associated with adipose tissue wasting in human studies (Lerner, Hayes et al., 2015) . White 74 adipose tissue (WAT) is a significant source of inflammatory cytokines accounting for more than 30% 75 of circulating interleukin (IL)-6 (Michaud, Boulet et al., 2014) and this and other inflammatory 76 cytokines have been linked to WAT atrophy in the setting of cancer (Petruzzelli, Schweiger et al., 77 5 composition and energy expenditure (Muller & Tschop, 2013) . In non-cancer models, it has been 86 shown to increase food intake by activating neuropeptide Y and agouti-related peptide-secreting 87 neurons in the hypothalamus and to have direct effects on adipocytes (Kos, Harte et al., 2009, 88 Muller & Tschop, 2013, Perez-Tilve, Heppner et al., 2011). Ghrelin has also been proposed as a 89 promising target for cancer cachexia and it has been shown to prevent fat atrophy in tumor-bearing In BAT, all the inflammatory markers were generally lower than in WAT. IL-1β was increased in both 142 genotypes ( Fig. 3A) and MCP-1 only in Ghsr -/- (Fig. 3D ). Ghrelin did not significantly affect these 143 changes. IL-6 and TNF levels were not significantly different between groups ( Fig. 3B-C) . 144 Nevertheless, immunohistochemistry analysis shows similar results as in iWAT suggesting that IL-6 145 and TNF in BAT were also derived exclusively from macrophages ( 
Ghrelin does not prevent the increases in UCP-1 induced by LLC in iWAT or BAT 151
Thermogenesis in BAT is activated by uncoupling protein-1 (UCP-1) by de-coupling oxidative 152 phosphorylation from ATP synthesis and dissipating heat in the inner mitochondrial membrane 153 (Puigserver, Wu et al., 1998) . A similar process has been reported in WAT which has been 154 described as "fat browning" with transformation of "white" to "beige" adipocytes (Rosen & 155 Spiegelman, 2014, Wu, Bostrom et al., 2012) . To test the effect of LLC and the role of ghrelin and 156 GHSR-1a on this pathway, we quantified UCP-1 levels in iWAT and BAT using 157 immunohistochemistry (IHC) by normalizing the positively-stained area to the total cross-sectional 158 area of the adipose tissue. Tumor implantation induced increases in UCP-1 expression in iWAT and 159 BAT in both genotypes and these increases were more pronounced in Ghsr -/than in Ghsr +/+ (Fig 4  160 A-D, genotype effect in BAT: p = 0.005). In iWAT, the LLC-induced UCP-1 increase only reached 161 significance in the tumor-bearing Ghsr -/mice and no significant effect of ghrelin was observed. In 162 BAT, the positively stained UCP-1 area increased with tumor implantation from 22% to 59% in 163 Ghsr +/+ and from 35% to 70% in Ghsr -/mice. However, no effect of ghrelin on reducing UCP-1 in 164 BAT was observed. 165 166
Tumor-induced increases in energy expenditure (EE) are not prevented by ghrelin 167
Tumor implantation increased EE and this difference was of greater magnitude in Ghsr -/animals 168 when the heat production was adjusted for lean body mass (LBM, normalized to baseline level, genotype effect: p = 0.013; average EE at endpoint, genotype effect: p 170 = 0.010). We also analyzed the raw EE data (kcal/h) by analysis of covariance (ANCOVA) with LBM 171 as a covariate as recommended by Tschop et al. (Tschop, Speakman et al., 2011) . A significant 172 strain difference (p = 0.001) was also detected using this method where Ghsr -/mice showed higher 9 EE levels in response to LLC tumor implantation when compared to Ghsr +/+ . Animals 174 co-administered ghrelin were not statistically different from vehicle-treated, tumor-bearing animals. 175
Tumor implantation also decreased spontaneous locomotor activity in both genotypes and ghrelin 176 administration did not prevent these changes ( uncoupling and whole-body energy expenditure. We confirmed that its orexigenic effects are 196 GHSR-1a-dependent, and also show that other novel GHSR-1a-independent mechanisms are 197 involved given the partial improvements in fat atrophy and WAT inflammation seen in ghrelin-treated, 198
Ghsr -/animals. Also, this is the first report of macrophages as the source of IL-6 and TNF in both 199 WAT and BAT in the setting of CACS. Previously, we have shown that activation of GHSR-1a by ghrelin or GHSR-1a agonists (GHS) 230 increases food intake and body weight (13, 39, 40). Our group and others also have shown that 231 ghrelin reduces fat oxidation and lipolysis and increases lipogenesis and adiposity in a rodent model 232 increased REE or decreased physical activity in the setting of CACS despite the fact that ghrelin 280 prevented fat and weight loss and anorexia. We hypothesize that differences in the models, route of 281 administration and treatment regimen and agents used (LLC mice vs. C26 mice or hepatoma model 282 in rats, administration via s.q. vs. oral gavage vs. osmotic mini pump, ghrelin vs. GHSR1a agonists) 283 could account for these discrepancies. More studies will be needed to test this hypothesis. however, the source of inflammation in BAT is not known. Similar to WAT, we found that BAT IL-6 291 and TNF come exclusively from macrophages in the setting of cachexia. However, their expression 292 in BAT were lower than in WAT and no significant changes were found in response to tumor 293 implantation or ghrelin. We found a significant tumor-effect on increasing IL-1β levels in BAT 294 although ghrelin did not prevent this increase, suggesting tissue-specific differences in inflammation 295 between BAT and WAT in response to tumor and ghrelin. Taken together, these results are 296 important because they show that tumor-induced WAT browning and BAT thermogenesis are 297 associated with significant increases in REE and appear to be independent of inflammation given 298 that downregulating inflammation does not prevent uncoupling in WAT and that BAT IL6 and TNF 299 levels were not upregulated upon tumor implantation. In addition, our data suggests that WAT is a 300 15 significant source of inflammatory cytokines, which express the highest levels of IL-1β, IL-6, and 301 TNF when compared to BAT and circulating levels. 302 303 There were limitations to our approach. This study was not set up to establish the safety of ghrelin 304 administration in the setting of cancer. Nevertheless, none of the studies published to date using 305 ghrelin or GHSR-1a agonists in mice or humans have shown an increase in tumor progression 306 (Sever, White et al., 2016) . Also, the experiments were not designed to characterize other 307 mechanisms contributing to the protective role of GHSR-1a in this setting. Lastly, our data suggest 308 that there is an alternative receptor for ghrelin although identification of this receptor remains elusive 309 and is the focus of other studies. 310
311
In summary, ghrelin prevents LLC tumor-induced body weight and fat loss by a combination of 312 GHSR-1a-dependent mechanisms including preventing anorexia, and other mechanisms that are 313 partly GHSR-1a-independent. The increase in inflammation in AT induced by tumor implantation is 314 prevented by ghrelin only in WAT; however, tumor-induced WAT browning, and increased BAT 315 inflammation, uncoupling and whole body energy expenditure are not prevented by ghrelin even 316 when the presence of GHSR-1a appears to contribute to maintaining energy balance in this setting. 317
Tumor-induced WAT browning and BAT thermogenesis are associated with significant increases in 318 REE and these seem to be independent of inflammation given that downregulating it does not 319 prevent these changes. These results are clinically relevant because they show that ghrelin 
Tumor implantation and ghrelin administration 341
The procedures of tumor implantation (TI) and ghrelin intervention were described previously (Chen 342 et al., 2015). In brief, mice were injected subcutaneously (s.q.) with Lewis lung carcinoma (LLC) 343 cells (1 × 10 6 cells, CRL1642, American Type Culture Collection, Manassas, VA) into the right flank 344 or with equal volume and number of heat-killed LLC cells (HK). Approximately 7 days after tumor 345 implantation (TI), when the tumor was palpable (~1cm in diameter), the tumor-bearing mice were 346 treated with either acylated ghrelin (AS-24160, Anaspect, Fremont, CA) at a dose of 0.8 mg/kg or 347 vehicle (0.9% sodium chloride, 8881570121, COVIDIEN, Dublin, Ireland), s.q., twice daily, while 348 mice in HK group received vehicle (saline, same volume), s.q., twice daily for two weeks. 
Comprehensive laboratory animal monitoring system (CLAMS™) 362
The Comprehensive Laboratory Animal Monitoring System (CLAMS™, Columbus Instruments, 363 Columbus, OH) was used to identify metabolic parameters of the animals as we previously 364 described (Guillory, Chen et al., 2017). Ghsr +/+ and Ghsr -/mice were individually housed in CLAMS 365 cages for 96 hours before TI as well as at the endpoint (see the Supplemental Fig. 5 , timeline for the 366 study). The first 12 hours of CLAMS was considered as the acclimation phase and the data for the 367 next 72 hours were analyzed. Oxygen consumption (VO 2 ) (mL/h), carbon dioxide production (VCO 2 ) 368 (mL/h), and locomotor activity (infrared beam-break counts) were recorded automatically by the 369 CLAMS system every 20 min. The respiratory exchange ratio (RQ) and energy expenditure (EE, or 370 heat generation) were calculated from VO 2 and VCO 2 gas exchange data as follows: RQ = 371 VCO 2 /VO 2 and EE = (3.815 + 1.232 × RQ) × VO 2 , respectively. Energy expenditure was then 372 18 normalized to LBM for statistical analysis using two-way analysis of variance (ANOVA). Alternatively, 373
we also analyzed EE value by ANCOVA with LBM as a covariate. Locomotor activity was measured 374 on x-and z-axes by the counts of beam-breaks during the recording period. The data shown in the 375 results was summarized as the mean of every 6 hours in a 72-hour-period. 376 377
Electrochemiluminescence immunoassay 378
Inflammatory cytokines IL-1β, IL-6, and TNF-α and macrophage marker MCP-1 in iWAT, BAT, and 379 serum were detected by U-PLEX Biomarker Group1 (ms) Assays which are developed by Meso 380 Scale Diagnostics (K15069L-1, MSD, Rockville, MD). A protocol provided by manufacturer was 381 used for this assay. In brief, each plate was prepared by overnight coating with the multiplex coating 382 solution at 4 o C, which contained linker-coupled biotinylated antibodies. Standards and serum 383 samples were diluted with Diluent 41 into 2-fold and loaded onto the coated plate on the next day. 384
For iWAT and BAT samples, 150ug of the protein lysate was diluted with Diluent 41 and loaded onto 385 each well. The plate was incubated at room temperature (RT) with shaking for 2h followed by 3 386 times of wash in phosphate buffered saline with .05% Tween 20 (PBS/T). Sulfo-tag labeled 387 detection antibody was then added to plates and incubated for 2.5h. After another 3 washes in 388 PBS/T, Read Buffer T(2x) was added and the plate was read on MSD Sector Imager (MSD). The iWAT and BAT were mounted with OCT (VWR 25608-930, VWR, Radnor, PA) and flash frozen 392 in liquid nitrogen-chilled isopentane immediately after tissue collection. The OCT-mounted iWAT 393 and BAT blocks were sliced at 14μm using a Cryostat (Leica CM3050S, Nussloch, Germany) at 394 -40 o C. Before the process of staining, slides were dehydrated at RT for 30 minutes followed by 395 incubating in methanol for 15 minutes at -20 o C. To identify the colocalization of F4/80 and IL-6 or 396 TNFα in iWAT and BAT, slides were blocked with 10% donkey serum for 1 hour at RT and followed 397 by incubating in primary antibodies (F4/80 Monoclonal Antibody 1:100, MF48000, Thermo Fisher 398 Scientific; Anti-IL-6 antibody 1:100, ab6672, Abcam; TNF alpha monoclonal antibody, FITC, 399 eBioscience™ 1:200, 11-7349-82, Thermo Fisher Scientific) at 4 o C for overnight. After 3 washes in 400 PBS, the slides were incubated by the corresponding secondary antibodies (Alexa Fluor 594 401 donkey anti-rat IgG, A21209, or Alexa Fluor 488 donkey anti-rat IgG, A21208, for F4/80; Texas Red 402 goat anti-rabbit IgG, T-2767, for IL-6) for 2 hours at RT and followed by incubating in 1:1000 DAPI 403 Two-way ANOVA was performed to identify differences between genotypes (Ghsr +/+ vs. Ghsr -/-) 419 across treatments (HK, TV, and TG) followed by Fisher's LSD post hoc test. For inflammatory 420 20 cytokines, Kruskal-Wallis test was performed to identify the differences between groups. For energy 421 expenditure, ANCOVA was also used for analysis in addition to ANOVA with LBM as a covariate to 422 identify differences between genotypes across treatments followed by Fisher's LSD post hoc test. 423 Values are presented in mean ± SEM. All statistical testing was performed using IBM SPSS version 424 18 software. Significant difference was set at *: p < 0.05; **: p < 0.01; ***: p < 0.001. 
